Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Medulloblastoma Imaging

  • Author: Djamil Fertikh, MD; Chief Editor: James G Smirniotopoulos, MD  more...
 
Updated: Dec 15, 2015
 

Overview

One half of primary brain tumors in children originate in the posterior fossa. Medulloblastomas are highly malignant tumors; they are the most common malignant posterior fossa tumor in the pediatric population. They are characterized by their tendency to seed along the neuraxis, following cerebrospinal fluid (CSF) pathways, and they represent one of the few brain tumors, including ependymoma, pinealoblastoma, and lymphoma, to metastasize to extraneural tissues. Originally classified as a glioma, medulloblastoma is now referred to as a primitive neuroectodermal tumor (PNET). (See the images below.)[1, 2, 3, 4, 5, 6, 7]

Medulloblastoma. Unenhanced CT shows a high-densit Medulloblastoma. Unenhanced CT shows a high-density midline tumor in the posterior fossa with a small amount of surrounding vasogenic edema exerting mass effect on the fourth ventricle, with a moderate degree of hydrocephalus.
Medulloblastoma in a 27-year-old man. Nonenhanced Medulloblastoma in a 27-year-old man. Nonenhanced sagittal T1-weighted image shows a poorly defined, laterally situated, hypointense cerebellar mass with a small cystic area.

Of medulloblastoma patients, 10-30% demonstrate CSF dissemination at diagnosis, mandating evaluation of the entire neuraxis with contrast-enhanced studies. Extra-axial metastases account for 5% of cases; most metastases are to the bone; less frequently, metastases are to the liver and lymph nodes.

Children with nondisseminated medulloblastoma have a high likelihood of long-term survival, with a 5-year survival rate of 80%. Intensified therapy has been shown to increase survival in children with disseminated disease. However, the quality of life in long-term survivors remains an important issue, because most survivors have neurologic and cognitive deficits.[8]

Medulloblastomas have been associated with basal nevus syndrome (Gorlin syndrome), Turcot syndrome, ataxia telangiectasia, xeroderma pigmentosum, and blue rubber bleb syndrome.

Standard treatment is surgery followed by radiation to the entire neuraxis. Medulloblastomas are radiosensitive. Gross total resection of the tumor, when possible, is the aim of surgery. Resection usually is achieved in 50% of patients, according to Thapar et al.[9]

Signaling pathways that regulate medulloblastoma tumor formation have been discovered. Advances in the molecular biology of medulloblastoma indicate that better understanding of the growth control mechanisms in medulloblastoma may lead to the development of new therapies for the disease.[10, 11]

Preferred examination

Although medulloblastoma has a highly characteristic appearance on computed tomography (CT) scanning, magnetic resonance imaging (MRI) is the preferred tool. The multiplanar capability of MRI provides better 3-dimensional visualization of the extent of the tumor, as well as better visualization of edema and herniation, when present. MRI also is better for evaluating the remainder of the neuraxis for metastasis. In addition, MRI spectroscopy may help better delineate the tumor's boundaries.[12, 13, 14, 15]  With CT scanning, only axial images can be obtained; by contrast, with MRI, any plane can be used for imaging. On CT scans, posterior fossa images often are degraded by beam-hardening artifacts.[16, 7, 17]

Next

Computed Tomography

Medulloblastomas are highly cellular; therefore, on noncontrast CT, their classic appearance is that of a high-density midline mass. In most patients (90%), a varying degree of hydrocephalus is apparent (see the image below.) Variable amounts of asymmetric edema are seen in approximately 90% of patients.

Medulloblastoma. Unenhanced CT shows a high-densit Medulloblastoma. Unenhanced CT shows a high-density midline tumor in the posterior fossa with a small amount of surrounding vasogenic edema exerting mass effect on the fourth ventricle, with a moderate degree of hydrocephalus.

On enhanced CT scans, a marked homogeneous enhancement of the tumor is seen (see the image below). In rare circumstances (13%), calcifications are found.

Medulloblastoma. Following intravenous injection o Medulloblastoma. Following intravenous injection of contrast material, the tumor shows marked diffuse and homogeneous enhancement.

Metastatic nodular seeding may be seen in the supratentorial subarachnoid space on contrast-enhanced CT scans and in the spinal canal on CT myelography.

Necrotic, cystic areas and hemorrhage are seen in approximately 10-16% and 3% of patients, respectively.

In a child, especially a boy, the presence of a high-density midline posterior fossa mass with diffuse marked enhancement is highly suspicious for medulloblastoma.

CT scanning is superior to MRI in depicting small punctate calcifications.

Previous
Next

Magnetic Resonance Imaging

Medulloblastomas are hypointense to isointense on T1-weighted images.[16, 17] (See the images below.)

Medulloblastoma in a 27-year-old man. Nonenhanced Medulloblastoma in a 27-year-old man. Nonenhanced sagittal T1-weighted image shows a poorly defined, laterally situated, hypointense cerebellar mass with a small cystic area.
Medulloblastoma. Axial MRI of the posterior fossa Medulloblastoma. Axial MRI of the posterior fossa shows a right-sided laterally located mass with mixed isointense and hyperintense signal intensity. Surrounding edema is seen as high signal intensity.
Medulloblastoma. Coronal T1-weighted postcontrast Medulloblastoma. Coronal T1-weighted postcontrast image shows a markedly enhancing peripheral tumor.
Medulloblastoma in a 6-year-old boy. Sagittal T1-w Medulloblastoma in a 6-year-old boy. Sagittal T1-weighted image shows a slightly hypointense mass in the region of vermis with compression of the fourth ventricle and obstructive hydrocephalus. The brain stem is also compressed by this mass. The lateral and third ventricles are dilated.
Medulloblastoma. Axial T1-weighted image shows a h Medulloblastoma. Axial T1-weighted image shows a hypointense mass in the midline, just posterior to the fourth ventricle. The fourth ventricle and brain stem are displaced anteriorly and compressed.
Medulloblastoma. Axial T1-weighted postcontrast im Medulloblastoma. Axial T1-weighted postcontrast image demonstrates an irregular, heterogeneous enhancing mass. Note the dilatation of both temporal horns, indicating obstructive hydrocephalus.

On T2-weighted images, appearances may vary from isointense to hyperintense. (See the image below.)

Medulloblastoma. Axial T2-weighted image reveals a Medulloblastoma. Axial T2-weighted image reveals a predominantly isointense mass to gray matter with small foci of cystic changes.

Medulloblastomas classically demonstrate heterogeneous hypointense or isointense signal. Calcifications appear as areas of signal void on T2-weighted images.

The pattern of enhancement after intravenous injection of gadolinium is similar to that after injection of iodinated contrast material on CT. However, the greater sensitivity of MRI often enables appreciation of a slightly heterogeneous enhancing pattern that is not as readily evident with CT.

Gadolinium-based contrast agents (gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [OptiMARK], gadoteridol [ProHance]) have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). For more information, see the eMedicine topic Nephrogenic Systemic Fibrosis. The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans.

NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.

The blurring of cerebellar folia and fissures, representing tumor spread via CSF pathways (best depicted on midline sagittal images), is a helpful sign. Subarachnoid or intraventricular seeding usually demonstrates contrast enhancement.

Drop metastases appear as high signal foci on contrast-enhanced T1-weighted images in the extramedullary and intradural space; occasionally, they are subpial in location.

Proton spectroscopy demonstrates a nonspecific elevation of the choline peak, representing cell membrane turnover; a decreased aspartate peak, representing loss of neuronal tissue; and variable lipid and lactate.

Because of the age group in which medulloblastomas occur, as well as the location and general appearance of the tumors, the degree of confidence usually is high with MRI.

Previous
Next

Nuclear Imaging

No findings specific to medulloblastoma have been described; however, single-photon emission CT (SPECT) and positron emission tomography (PET) scanning complement CT scanning and MRI. Although the mechanism of uptake is not clearly understood, 80% of pediatric tumors show uptake of thallium-201 chloride (201 TI). These techniques also are important in differentiating high-grade from low-grade tumors and residual tumor from postoperative changes.

Thallium SPECT and fluorine-18-flurodeoxyglucose PET are complementary in diagnosing gliomas, although thallium SPECT was found to correlate more significantly with malignancy. In a series of 19 patients, Kahn et al demonstrated that the sensitivity and specificity for tumor recurrence is 69% and 40%, respectively, for201 TI, and 81% and 40%, respectively, for PET.[18]

Previous
Next

Angiography

Angiographic findings are not diagnostic. Medulloblastoma may demonstrate abnormal neovascularity. Because medulloblastoma is a posterior fossa tumor, anterior displacement of the precentral cerebellar vein may be seen. Posterior and inferior displacement of the inferior vermian vein also may be seen. Angiographic findings are nonspecific for the diagnosis of medulloblastoma and are only indicative of a space-occupying lesion.

Previous
 
Contributor Information and Disclosures
Author

Djamil Fertikh, MD Attending Radiologist, Association of Alexandria Radiologists

Djamil Fertikh, MD is a member of the following medical societies: American College of Radiology, American Society of Neuroradiology, American Medical Association, Radiological Society of North America

Disclosure: Nothing to disclose.

Coauthor(s)

Michael L Brooks, MD, JD FCLM, Clinical Associate Professor of Radiology, Drexel University School of Medicine, Adjunct Clinical Associate Professor of Radiology, Philadelphia College of Osteopathic Medicine; Director of Neuroradiology, Mercy Diagnostic Imaging, Department of Radiology, Mercy Fitzgerald Hospital

Michael L Brooks, MD, JD is a member of the following medical societies: American College of Legal Medicine, American College of Radiology, American Society of Neuroradiology, American Society of Pediatric Neuroradiology, American Society of Spine Radiology

Disclosure: Nothing to disclose.

Specialty Editor Board

Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand

Disclosure: Nothing to disclose.

C Douglas Phillips, MD, FACR Director of Head and Neck Imaging, Division of Neuroradiology, New York-Presbyterian Hospital; Professor of Radiology, Weill Cornell Medical College

C Douglas Phillips, MD, FACR is a member of the following medical societies: American College of Radiology, American Medical Association, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, Radiological Society of North America

Disclosure: Nothing to disclose.

Chief Editor

James G Smirniotopoulos, MD Professor of Radiology, Neurology, and Biomedical Informatics, Program Director, Diagnostic Imaging Program, Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences

James G Smirniotopoulos, MD is a member of the following medical societies: American College of Radiology, American Roentgen Ray Society, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, Radiological Society of North America, American Society of Pediatric Neuroradiology

Disclosure: Nothing to disclose.

Additional Contributors

Chi-Shing Zee, MD Chief of Neuroradiology, Professor, Departments of Radiology and Neurosurgery, Keck School of Medicine of the University of Southern California

Chi-Shing Zee, MD is a member of the following medical societies: American Society of Neuroradiology

Disclosure: Nothing to disclose.

References
  1. Bloom HJ, Glees J, Bell J, et al. The treatment and long-term prognosis of children with intracranial tumors: a study of 610 cases, 1950-1981. Int J Radiat Oncol Biol Phys. 1990 Apr. 18(4):723-45. [Medline].

  2. Rutka JT. Medulloblastoma. Clin Neurosurg. 1997. 44:571-85. [Medline].

  3. Zee CS, Segall HD, Nelson M. Infratentorial Tumors in Children. Neuroimaging Clinics of North Am. 1993. 3(4):705-714.

  4. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008 Nov. 65(11):1419-24. [Medline].

  5. Yazigi-Rivard L, Masserot C, Lachenaud J, Diebold-Pressac I, Aprahamian A, Avran D, et al. [Childhood medulloblastoma.]. Arch Pediatr. 2008 Nov 6. [Medline].

  6. Karajannis M, Allen JC, Newcomb EW. Treatment of pediatric brain tumors. J Cell Physiol. 2008 Dec. 217(3):584-9. [Medline].

  7. Hoang DH, Pagnier A, Guichardet K, Dubois-Teklali F, Schiff I, Lyard G, et al. Cognitive disorders in pediatric medulloblastoma: what neuroimaging has to offer. J Neurosurg Pediatr. 2014 Aug. 14 (2):136-44. [Medline].

  8. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008 Nov. 65(11):1419-24. [Medline].

  9. Thapar K, Laws ED. Tumors of the central nervous system. In: Clinical Oncology. Am Cancer Soc. 1995:396-7.

  10. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res. 2008 Feb 15. 14(4):971-6. [Medline].

  11. Pomeroy SL, Sturla LM. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg. 2003 Dec. 39(6):299-304. [Medline].

  12. Lizak P,, Woodruff W. Posterior fossa neoplasms: Multiplanar imaging. Sem.Ultrasound CT MRI. 1992. 13:182-206.

  13. Stark DD, Bradley WG. Medulloblastoma. In: Magnetic Resonance Imaging. 3rd ed. Mosby-Year Book. 1999:1474.

  14. MacDonald SM, Desai N, Heller G, Rolnitzky L, Allen JC. MRI changes in the "normal" pineal gland following chemotherapy for suprasellar germ cell tumors. Pediatr Hematol Oncol. 2008 Jan-Feb. 25(1):5-15. [Medline].

  15. Komatsu F, Tsugu H, Nonaka M, Tsutsumi M, Yanai F, Yukitake K, et al. Congenital medulloblastoma with atypical MRI appearance. Pediatr Neurosurg. 2008. 44(2):165-8. [Medline].

  16. Patay Z, DeSain LA, Hwang SN, Coan A, Li Y, Ellison DW. MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma. AJNR Am J Neuroradiol. 2015 Sep 3. [Medline].

  17. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2014 Jul. 35 (7):1263-9. [Medline].

  18. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F- fluorodeoxyglucose PET. AJR Am J Roentgenol. 1994 Dec. 163(6):1459-65. [Medline].

 
Previous
Next
 
Medulloblastoma. Unenhanced CT shows a high-density midline tumor in the posterior fossa with a small amount of surrounding vasogenic edema exerting mass effect on the fourth ventricle, with a moderate degree of hydrocephalus.
Medulloblastoma. Following intravenous injection of contrast material, the tumor shows marked diffuse and homogeneous enhancement.
Medulloblastoma in a 27-year-old man. Nonenhanced sagittal T1-weighted image shows a poorly defined, laterally situated, hypointense cerebellar mass with a small cystic area.
Medulloblastoma. Axial MRI of the posterior fossa shows a right-sided laterally located mass with mixed isointense and hyperintense signal intensity. Surrounding edema is seen as high signal intensity.
Medulloblastoma. Coronal T1-weighted postcontrast image shows a markedly enhancing peripheral tumor.
Medulloblastoma in a 6-year-old boy. Sagittal T1-weighted image shows a slightly hypointense mass in the region of vermis with compression of the fourth ventricle and obstructive hydrocephalus. The brain stem is also compressed by this mass. The lateral and third ventricles are dilated.
Medulloblastoma. Axial T1-weighted image shows a hypointense mass in the midline, just posterior to the fourth ventricle. The fourth ventricle and brain stem are displaced anteriorly and compressed.
Medulloblastoma. Axial T2-weighted image reveals a predominantly isointense mass to gray matter with small foci of cystic changes.
Medulloblastoma. Axial T1-weighted postcontrast image demonstrates an irregular, heterogeneous enhancing mass. Note the dilatation of both temporal horns, indicating obstructive hydrocephalus.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.